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Controlled synthesis of hollow polymeric nanocapsules has attracted signiﬁcant attention in a wide range of
applications. This paper reports a facile method for the synthesis of hybrid starch nanocapsules decorated
with silver nanoparticles using the inverse miniemulsion polyaddition technique. Silver nanoparticles are
formed and embedded in the shell of the nanocapsules during the polyaddition process without using
any additional reducing agents. We found that silver also acts as a lipophobe that builds up osmotic
pressure in the droplets facilitating the formation of stable round shaped nanocapsules. The
nanocapsules' shell thickness could be tuned from 13 to 29 nm by varying the amount of cross-linker.
We investigated the minimum inhibitory concentration (MIC) of the nanocapsules against
Staphylococcus epidermidis ATCC 35984 and Escherichia coli ATCC 25922 which are two bacteria of
medical relevance. The silver nanoparticle decorated nanocapsules showed antibacterial properties
against both bacteria at the MIC of 2.315 mg mL1 while control nanocapsules without silver had no
antibacterial activity.1. Introduction
Infections are the second leading cause of death worldwide
aer heart diseases. The importance of the problem has led to
extensive prevention and treatment eﬀorts. However, despite
great examples of success, infections are still part of our
society causing suﬀering, death and substantial burden to the
healthcare systems.1,2 Today, the main weapons to ght
infections are antibiotics. This therapy saved millions of lives
over the last 60 years; however, it has some disadvantages.3
One of the major problems is the phenomenon associated with
antimicrobial resistance.4,5 Since the 1970s, a trend to
returning to silver and silver based compounds aer the
development of antibiotic resistance has emerged.6,7 Over the
last two decades, there has been increased interest in the use
of silver, silver compounds and silver nanoparticles in medical
applications. Examples are coatings for applications on wound
dressing8,9 and medical devices such as catheters.10,11 Ath Australia, Mawson Lakes, SA 5095,
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–1845number of commercial silver and silver nanoparticle con-
taining products are currently on the market. A vast number
of research papers on the subject have also been published.
For further reading, we direct the reader to several recent
reviews on the topic.12–19 The reasons for this trend are that
silver is universally active against all bacteria and not limited
to certain bacterial types as antibiotics. Importantly, there is
no convincing evidence that medically relevant bacteria are
capable of developing resistance to silver.20,21
The goal of this work is to generate advanced biocompatible
nanocapsules which are decorated with silver nanoparticles.
Nanocapsules have been shown to be promising carries of drugs
and other therapeutic molecules.22 The underlying motivation
is to add antibacterial properties to nanocapsules' transport
capability. We selected miniemulsion polymerization to achieve
our goal. The technique is facile and provides molecular control
over nanocapsule dimensions, structure and chemical compo-
sition.22 Narrowly distributed small droplets resulting from this
process can act as nano-carriers or nano-reactors which makes
them attractive in many applications such as targeted drug
delivery systems,23,24 self-healing coatings,25–27 and optical
molecular imaging.28 The technique has already been demon-
strated for the successful encapsulation of a variety of materials
such as nanoparticles, pigments, polymers, fragrances, drugs,
and photoinitiators.22,29 We chose potato starch as the organic
component for generating the nanocapsule wall structure
because of its biocompatible and biodegradable nature.30 Starch
nanocapsules have already been demonstrated as drug carriersThis journal is © The Royal Society of Chemistry 2014




















































































View Article Onlinewith potential in targeted drug delivery and therapies.31,32
This study further aims to demonstrate the capacity to control
the capsule wall thickness. In addition, we aim to provide
functional chemical groups of the outer wall of the capsules
which can be used for attachment of ligands for diﬀerent
applications (i.e. antibodies for cell targeting) or immobiliza-
tion to surfaces.2. Experimental
2.1. Materials
All reagents were used as received without further purication.
The hydrophilic water-soluble potato starch MW 15 000 g mol1
(determined by GPC-MALLS) was purchased from Fluka. Silver
nitrate (AgNO3, 99.99%), 2,4-toluene diisocyanate (TDI) and
cyclohexane (>99.9%) were purchased from Sigma Aldrich. The
oil soluble surfactant polyglycerin-polyricinoleat (PGPR) was
purchased from Danisco (GRINDSTED®PGPR). The non-ionic
surfactant Lutensol AT50, which is a poly(ethylene oxide)-
hexadecyl ether with an EO block length of about 50 units,
was provided by BASF. Sterilized water aqua ad iniectabilia
was obtained from Braun. Monochloroacetic acid (MCA) was
purchased from Aldrich.2.2. Instrumental
A PSS Nicomp Particle Sizer 380 (Nicomp Particle Sizing
Systems, USA) was used to measure the average size and size
distribution of the nanocapsules. High resolution scanning
electron microscopy (SEM) (Hitachi S-5200) and Transmission
Electron Microscopy (TEM) (Philips CM200) were carried out to
determine the particles' morphology. Samples were prepared by
drying a droplet of diluted samples on silicon wafer for SEM and
carbon coated copper grids for TEM. FTIR measurements were
carried out using a Perkin Elmer Spectrum BX in the spectral
range between 4000 and 400 cm1 to determine the chemical
composition of the nanocapsules. The equipment used for
measuring the particle charge of nanocapsules was PCD 02
(Mu¨tek Company) equipped with a Mettler DL21 Titrator. The
amount of silver present in nanocapsules was analyzed by
inductively coupled plasma (ICP) spectroscopy using a Perkin
Elmer ICP-OES Optima 7300 DV to analyze Ag (mg L1). The
reading wavelength for Ag was 328.068 nm and the collected
data were processed with MSF (Multicomponent Spectral
Fitting).Table 1 Formulations used in the synthesis of nanocapsules
Sample name
Chemistry
AgNO3 (mg) H2O (g) Starch (mg) TDI (mg)
S043 57 1.3 100 200
S044 57 1.3 100 150
S045 57 1.3 100 100
S046 0 1.3 100 200
S047 0 1.3 100 150
S048 0 1.3 100 1002.3. Solid content measurement
The solid content of each sample was measured gravimetrically.
An empty scintillation vial was weighed and the weight was
recorded to the nearest thousandth of a gram (A). 100 mL of
sample was then added to the vial and the weight was recorded
(B). The specimen was then placed in an oven with temperature
set at 105 C for 3 hours. The dried specimen was then removed
from the oven and the weight was recorded to the nearest
thousandth of a gram (C). The following equation calculates the
percent of solidsThis journal is © The Royal Society of Chemistry 2014%Total solid ðsolid contentÞ :"
weight of dried sample plus dish ðCÞ
weight of empty dish ðAÞ
#
"
weight of original sample plus dish ðBÞ
weight of empty dish ðAÞ
# 100 (1)
2.4. Synthesis of starch–silver nanocapsules
First, an aqueous solution consisting of 0.057 g AgNO3, 1.300 g
sterilized water and 0.100 g soluble potato starch was
prepared. To this phase, 7.400 g of cyclohexane pre-mixed with
0.100 g PGPR was added and stirred at 1000 rpm for one hour
at 25 C using a magnetic stirrer. Then the mixture was
ultrasonicated for 180 s at 90% amplitude in a pulse regime
(20 s sonication, 10 s pause) using a Branson Sonier W-450-
Digital and a 1/20 0 tip under ice cooling conditions in order to
prevent evaporation of the solvent. Diﬀerent amounts (0.200,
0.150 and 0.100 mg) of TDI dissolved in 4.970 g of cyclohexane
and pre-mixed with 0.030 g PGPR were added dropwise over
5 min to the previously prepared emulsion under stirring
conditions while maintaining the temperature at 25 C. The
mixture was kept under stirring overnight at 25 C. The min-
iemulsion samples were then dispersed in 0.3% Lutensol AT50
at a ratio of 1 : 5. Another set of samples was prepared
according to the procedure described above but without
AgNO3. The designation and formulation compositions used
in this study are denoted in Table 1.
2.5. Carboxymethylation of starch–silver nanocapsules
The carboxymethylation of starch–AgNP nanocapsules was
performed using a method published previously.24 Briey, 0.4
mL of NaOH solution (0.1 M) was added to 4.0 g of starch–AgNP
re-dispersion nanocapsules (solid content 1.0 wt%) and stirred
at ambient temperature for 24 h to neutralize the non-reacted
hydroxyl groups of the starch molecules on the nanocapsule
surface. Next, 40 mL of MCA (20.0 wt%) was mixed with the
above mentioned dispersion and stirred for 24 h at 40 C. Then
0.2 mL of NaOH solution (1.0 M) was added to the solution and
stirred again for 24 h at ambient temperature. Finally, the
nanocapsule dispersion was centrifuged at 4000 rpm for 20 min
(Sigma 3k-30, RCF 1467) and aer removing the supernatant
starch–AgNP nanocapsules were redispersed in demineralized
water. The amount of carboxylic groups was determined by theJ. Mater. Chem. B, 2014, 2, 1838–1845 | 1839




















































































View Article Onlinepolyelectrolyte titration method described below. Carboxyl acid
groups were titrated against poly-DADMAC using 10 mL of the
dispersion with a solid content of 0.01 g L1 at a pH of 10. Each
sample was titrated in triplicate, the number of carboxyl acid
groups per nm2 was determined from the average consumed





the quantity of charged groups per nm2

(2)
½groups per particle ¼ groups per gpolymer rDn3pSC ðthe quantity of charged groups per particleÞ (3)

groups per nm2
 ¼ groups per gpolymer rDn10186 ðthe quantity of charged groups per square unitÞ (4)V¼ volume of the consumed polyelectrolyte in liters,M¼molar
concentration of the polyelectrolyte in moles per liter, F ¼
density of polystyrene (1.045  106 g L1), NA ¼ Avogadro's
constant, SC ¼ solid content of the sample in grams, Dn ¼
average number diameter of the particle.2.6. Determination of antibacterial activity in vitro
Staphylococcus epidermidis (ATCC 35984) and Escherichia coli
(ATCC 25922) were used because these are common microor-
ganisms involved in hospital-acquired infections. The nano-
capsules were assayed for activity against these two strains in
vitro.34 Bacteria were plated on Luria–Bertani agar plates from
frozen stocks and incubated at 37 C. Individual bacterial colonies
were picked and incubated overnight at 37 C in the oven. Nano-
capsuleswerewashed and serially diluted in quadruplicate in a 96
well microtiter plate with a nal volume of 50 mL per well. ABS600
wasused to adjust to approximately 1 108CFUmL1 and further
diluted to 1.33 106 CFUmL1 in tryptic soya broth (TSB). A total
of 150mLofbacterial suspensionwas added toeachwell to achieve
a nal concentration of approximately 1  106 CFU mL1. Bacte-
rial suspensions without nanoparticles and wells containing
particles and TSB without bacteria were used as controls. Using a
microtiter plate reader (Biotek, ELx800), the minimal inhibitory
concentration (MIC, the lowest concentration of an antimicrobial
that will inhibit the visible growth of a microorganism aer
overnight incubation) values were determined by measuring the
turbidity of thebacterial suspensionaer24h incubationat 37 C.
The eﬀect of light scattering induced by the nanocapsules was
taken into account when reading ABS600. The results were
conrmed visually. All assays were performed in triplicate.3. Results and discussion
The general approach to synthesize potato starch nanocapsules
with AgNPs embedded within their walls is shown in Fig. 1a. A1840 | J. Mater. Chem. B, 2014, 2, 1838–1845macroemulsion is rst prepared by mixing potato starch and
silver nitrate in aqueous medium with an amphiphilic surfac-
tant polyglycerin-polyricinoleate (PGPR) in cyclohexane. A
miniemulsion is then generated by sonication of this mixture in
order to achieve homogenous aqueous droplets in the cyclo-
hexane phase. In a next step 2,4-toluene diisocyanate (TDI) isadded in order to facilitate the formation of the core–shell
structure of starch–AgNP nanocapsules via polyaddition. The
nanocapsule shell is formed by cross-linking of the starch OH
groups with the –NCO groups of TDI. The mixture is then
transferred from cyclohexane to an aqueous medium using the
non-ionic surfactant Lutensol AT50, and this surfactant facili-
tates the redispersion of oil soluble nanocapsules into the water
phase. In this synthetic procedure the starch acts as a reducing
agent for silver nitrate. Reduction of silver nitrate into metallic
silver occurs during the polyaddition and cross-linking steps
facilitated by the release of free radicals35 and D-glucose from
the amylose component of starch.36,37 The nanocapsules were
stable over several months in both the hydrophobic continuous
phase (cyclohexane) and when redispersed in water (data not
shown). The characteristic surface plasmon resonance (SPR)
bands of AgNPs with the absorption maxima at around 412 nm
are evidence for the presence of AgNPs in the nanocapsule
solution (Fig. 2), and the inset in Fig. 2 shows the resultant
solution of starch silver nanocapsules (grayish brown color)
versus the starch only nanocapsules. The purple color of starch
only nanocapsules is as a result of addition of sulforhodamine
101 (SR101) uorescent dye (data not shown).
The proportion of non-volatile material contained in the
miniemulsions le aer the volatile solvent (water or cyclo-
hexane) vaporized in the oven was calculated and expressed in
the form of solid content (%) (Table 2). The loss in solid content
of the redispersed sample is due to ltration of nanocapsules.
The average sizes of the nanocapsules were determined by
dynamic light scattering and are shown in Table 2. Formula-
tions without addition of AgNO3 (S046, S047 and S048) resulted
in capsules in the size range of 700–800 nm.
SEM imaging further revealed that these nanocapsules are
smaller in size but they were agglomerated and substantially
deformed. A representative image of this type of nanocapsule is
shown in Fig. 3d–f. When the synthesis was conducted in the
presence of AgNO3, a capsule size of 290–370 nm was achieved.This journal is © The Royal Society of Chemistry 2014
Fig. 1 Schematic of the procedure applied for synthesizing starch–AgNP nanocapsules.
Fig. 2 UV-visible spectra of starch–silver nanocapsules versus starch
only nanocapsules; the inset shows the appearance of the mini-
emulsion solutions.




















































































View Article OnlineThe SEM images of nanocapsules prepared with diﬀerent
amounts of TDI are shown in Fig. 3a–c. The images depict stable
hollow spherical entities. Due to drying and vacuum required
for SEM imaging the nanocapsules appear like hollow half balls.Table 2 Characteristics of nanocapsules: solid content, DLS size determ




S043 AgNP–starch nanocapsules 1.96 0.29
S044 1.71 0.44
S045 0.84 0.46
S046 Starch nanocapsules 0.50 0.37
S047 0.87 0.36
S048 1.14 0.41
a The amount of carboxylic groups was measured on redispersed samples. b
using Lutensol AT50.
This journal is © The Royal Society of Chemistry 2014The images also show bright entities within the walls of the
nanocapsules which are assigned to silver nanoparticles. The
presence of metallic silver in the walls of the nanocapsules was
also conrmed by energy-dispersive X-ray (EDX) spectroscopy
which is discussed later in the paper (Fig. 5). It is interesting to
note that the silver nanoparticles do not appear clear in the
images of the nanocapsules presented in Fig. 3a. The reason for
this is the greater shell wall thickness. These nanocapsules were
synthesized using the highest amount of TDI. The dependence
of the shell wall thickness on the concentration of TDI is dis-
cussed later in the paper. The SEM observations are an indi-
cation of the important role of AgNO3 as an osmotic pressure
agent.38 Silver nitrate as an inorganic salt is insoluble in the oil
phase and can act as a lipophobe that builds up an osmotic
pressure in the droplets.39 Thus, silver ions may be capable of
suppressing Ostwald ripening and in this manner facilitate the
formation of a well-dened core–shell structure. Analysis of the
SEM images in Fig. 3a–c using the ImageJ soware packageination and carboxyl acid functionalities
Mean diameter (nm)









287.3 236.2 3.27  1018 2.36  104 0.13
373.8 147.1 4.09  1018 7.13  103 0.10
291.0 157.5 4.03  1018 8.63  103 0.11
815.8 527.9 3.05  1018 2.46  105 0.28
716.4 716.0 3.63  1018 7.30  105 0.45
807.5 445.7 4.05  1018 1.96  105 0.31
Redispersion: dispersion of oil soluble nanocapsules in the water phase
J. Mater. Chem. B, 2014, 2, 1838–1845 | 1841
Fig. 3 SEM images of starch nanocapsules with and without silver nanoparticles: (a) S043, (b) S044, and (c) S045 which were synthesized with
AgNO3 and (d) S046, (e) S047, and (f) S048 which were synthesized without AgNO3.




















































































View Article Onlinesuggested round shaped silver nanoparticles of 14 nm diameter
and a narrow size distribution. Furthermore, the size of the
silver nanoparticles does not seem to be aﬀected by the shell
thickness. We calculated an average of 5.5 silver nanoparticles
per each 100 nm2 of the shell surface area. We hypothesize that
the growth of nanoparticles is controlled during the formation
of the nanocapsules' shell structure.
An SEM backscattered electron image of the silver nano-
particle containing nanocapsules is shown in Fig. 4a. Silver
nanoparticles appear as bright points because of their capacity
to scatter a larger number of electrons. EDX spectra recorded at
positions 25 and 26 of the image presented in Fig. 4a are shown
in Fig. 4b. Several peaks can be identied. These peaks are
representative of the chemical composition of the nano-
capsules. The peak at 3 keV is characteristic of the silver K and L
lines and evidence for the presence of silver nanoparticles. The
peak at 0.2 keV represents carbon. The peaks located at 0.38 and
0.5 keV are associated with the nitrogen and oxygen character-
istic lines, respectively. The sodium line comes from the
surfactants used in the formulation. There is a small Si line
which is from the silicon wafer substrate used as a support. TheFig. 4 (a) An SEM backscattered electron image; (b) EDX spectrum
nanocapsules.
1842 | J. Mater. Chem. B, 2014, 2, 1838–1845distribution map of Ag is shown in Fig. 4c and shows a discrete
and uniform distribution of silver in the nanocapsules.
The nanocapsule shell wall thickness was determined from
the SEM images. Fig. 5 shows shell wall thicknesses as a func-
tion of the TDI amount used in the synthesis for formulations
involving AgNO3. It appears that the amount of added TDI
signicantly inuences the nanocapsule shell thickness. As a
general trend, the nanocapsule shell wall had a greater thick-
ness with increasing TDI amount. For example, formulations
S043, S044 and S045 where the TDI amount was 200, 150 and
100 mg had the shell thickness of 29 nm, 20 and 13 nm,
respectively (Fig. 5).
Further insight into the distribution and size of the silver
nanoparticles was revealed by TEM imaging. The TEM images
in Fig. 6b demonstrate that a number of small 3–6 nm silver
nanoparticles, which are beyond the resolution of SEM, are also
available. On rare occasions we also observed the formation of
some larger silver nanoparticles on a few tenths of nanometers
as shown in the TEM image in Fig. 6a. The larger particles
appear to have formed out of the nanocapsules and thus their
growth has not been restricted by the walls.and (c) EDX image of the distribution of silver in the starch–silver
This journal is © The Royal Society of Chemistry 2014
Fig. 5 Shell thickness versus the TDI amount used in the synthesis.
Fig. 6 TEM micrographs of a starch–silver nanocapsule (a) and a
magniﬁed image showing the capsule wall and smaller silver nano-
particles (b).




















































































View Article OnlineFTIR spectroscopy was applied to study the chemical
composition of the samples (Fig. 7). The peak at 2276 cm1
could be assigned to NCO groups; however, its low intensity
suggests that in the nal redispersed product most of these
groups were consumed by the hydrolysis reaction with water to
form amines.40 A close examination of FTIR spectra suggests
that the incorporation of silver nanoparticles does not lead to
changes in the chemical composition of nanocapsules as in
both compositions peaks identied with chemical bondsFig. 7 FTIR spectra of the starch nanocapsules synthesized with (a)
and without silver nitrate (b).
This journal is © The Royal Society of Chemistry 2014appear at the same frequencies. The presence of hydrogen
bonded –OH stretching and NH valence vibration (which is
overlapped by O–H vibration) is evident in the form of a broad
band in the region of 3600–3200 cm1. A strong band at 2899
cm1 is characteristic of the presence of CH (sp3) stretching in
the aromatic structure. The weak broad band at 1968 cm1 is
attributed to N–H/C–N groups. Free C]O vibration and poly-
urethane C]O vibration are observed at 1734 and 1700 cm1,
respectively. The weak broad band at 1640 cm1 is due to the
formation of polyurea. The bands observed in the region of
1650–1450 cm1 also indicate C]C vibration in the aromatic
ring. C–O–C anti-symmetric bridge stretching is observed at
1150 cm1 in the form of a medium intensity band (cm1). The
bands at 1467 and 1343 cm1 are attributed to CH2 and CH
bending respectively. The strong bands at 1300 and 1100 cm1
are assigned to the C–(C]O)–C bending and C–O valence
vibration. A strong band at 1060 cm1 mainly originates from
the tertiary alcohol (R–C(CH3)–OH). The bands at 963, 842, 717
and 529 cm1 are also attributed to the skeletal vibrations of the
polymeric shell.
The outer shell wall of the nanocapsules was further func-
tionalized by carboxymethylation41 in order to provide appro-
priate chemical functionalities which could be used for
chemical immobilization on surfaces42 when targeted applica-
tions are antibacterial coatings or/and the attachment of
proteins or other ligands.40,43–45 The amount of carboxylic
groups on the nanocapsule surface was determined by poly-
electrolyte titration and the results are presented in Table 2. The
average COOH functionalities in the samples containing AgNPs
are in the range of 0.1–0.13 group per nm2 and in pure starch
nanocapsules they are between 0.28 and 0.45 group per nm2.
Such functional group densities are believed to be suﬃcient for
immobilization purposes and also provide a suﬃcient number
of binding sites for attachment of ligands or proteins.
The concentration of silver based on ICP analysis was 37 mg
mL1. The decrease in the silver concentration compared to the
initial amount used in the synthesis can be attributed to
removal of silver nanoparticles which were not embedded in
nanocapsule walls during the washing and centrifuge steps.
Finally, we examined the MIC of the nanocapsules against
Staphylococcus epidermidis (S. epidermidis) and Escherichia coli
(E. coli). These two bacteria pose a signicant medical problem
and cause a substantial part of the infections. The concen-
tration of bacteria used for determination of the MIC values
was 1  106 CFU mL1. The minimum concentration of
starch–silver nanocapsules required for inhibition of bacteria
growth was studied by serial dilution. We found that a very low
concentration of starch–silver nanocapsules was able toTable 3 MIC of starch–silver nanocapsules (S043) against Staphylo-
coccus epidermidis ATCC 35984 and Escherichia coli ATCC 25922
Bacteria MIC (mg mL1)
S. epidermidis ATCC 35984 2.315a
E. coli ATCC 25922 2.315a
a The mean values are shown with STD: <0.5.
J. Mater. Chem. B, 2014, 2, 1838–1845 | 1843




















































































View Article Onlineinhibit the bacteria growth. These concentrations are shown
in Table 3 and were 2.315 mg mL1 for both S. epidermidis and
E. coli. The growth was completely inhibited at 2.315 mg mL1
in starch–silver nanocapsules while starch nanocapsules
without silver nanoparticles had no inhibitory eﬀect on
bacterial growth.
Generation of hybrid polymeric/metallic nanocapsules in a
controllable manner is a challenging task.22,46–48 In this work, we
were able to employ the miniemulsion technique in combina-
tion with polyaddition polymerization to prepare in a control-
lable manner silver nanoparticles that are incorporated in the
walls of potato starch nanocapsules. These nanocapsules have
strong antibacterial properties with MICs in the range of a few
micrograms per milliliter for S. epidermidis (Gram-positive) and
E. coli (Gram-negative). This type of antibacterial nanocapsule
could be of interest in biomedical applications because they
might be capable of reducing the rates of infections when such
carriers are used in drug delivery. The material is also inter-
esting because starch is biodegradable, which means that it
would be broken down by natural physiological processes if
delivered into the body. Current work in our lab is focused on
immobilization of these starch–silver nanocapsules to solid
surfaces for applications as antibacterial coatings that can be
applied to wound dressing and implantable biomedical devices.
We are also exploring loading of various therapeutic agents in
these hybrid nanocapsules that can be delivered either via solid
carriers or in a suspension form.
4. Conclusion
In summary, we report a facile method for synthesis of hollow
starch nanocapsules decorated with silver nanoparticles. The
addition of AgNO3 seems to play an important role facilitating
the formation of stable spherical nanocapsules. The nano-
capsule wall thickness can be controlled by the amount of TDI
used in the synthesis. We were able to conduct further surface
modication of the nanocapsule walls in order to provide
carboxyl functional groups which can be potentially used for
the surface immobilization or binding of ligands of interest
for a particular application. The silver nanoparticles were
formed in capsule walls and had diameters of about 14 nm.
However, TEM images revealed the presence of some quantity
of smaller particles. Occasionally, large nanoparticles of a few
tenths of nanometers were also observed but they appear to
have grown outside of capsule walls. MIC studies showed high
antibacterial eﬃcacy against Staphylococcus epidermidis ATCC
35984 and Escherichia coli ATCC 25922. The biocompatible
nanostructures presented in this paper are of potential
interest for various biomedical applications such as smart
drug carriers and antibacterial coatings for medical devices
and wound dressings.
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